Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 182

1.

Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study.

Scala C, Leone Roberti Maggiore U, Barra F, Venturini PL, Ferrero S.

Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:89-94. doi: 10.1016/j.ejogrb.2018.01.022. Epub 2018 Feb 3.

PMID:
29408753
2.

Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.

Johnson-Agbakwu C, Brown L, Yuan J, Kissling R, Greenblatt DJ.

Clin Ther. 2018 Jan;40(1):64-73. doi: 10.1016/j.clinthera.2017.08.021. Epub 2017 Dec 2.

3.
4.

Phototoxic reaction to a combined oral contraceptive (levonorgestrel/ethinylestradiol).

Richarz NA, Aguilera J, Castillo G, Fuente MJ, Ferrándiz C, Carrascosa JM.

Photochem Photobiol Sci. 2017 Sep 13;16(9):1381-1383. doi: 10.1039/c7pp00160f.

PMID:
28825075
5.

Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.

Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, Sasaoka S, Fukuda A, Naganuma M, Hirade K, Takahashi Y, Kinosada Y, Nakamura M.

PLoS One. 2017 Jul 21;12(7):e0182045. doi: 10.1371/journal.pone.0182045. eCollection 2017.

6.

Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent.

Olatunji LA, Michael OS, Adeyanju OA, Areola ED, Soladoye AO.

Pharmacol Rep. 2017 Jun;69(3):512-519. doi: 10.1016/j.pharep.2016.12.010. Epub 2016 Dec 19.

PMID:
28349880
7.

Endogenous thrombin potential changes during the first cycle of oral contraceptive use.

Westhoff CL, Pike MC, Cremers S, Eisenberger A, Thomassen S, Rosing J.

Contraception. 2017 May;95(5):456-463. doi: 10.1016/j.contraception.2017.01.001. Epub 2017 Jan 11.

8.

Comparison of combined hormonal vaginal ring and low dose combined oral hormonal pill for the treatment of idiopathic chronic pelvic pain: a randomised trial.

Priya K, Rajaram S, Goel N.

Eur J Obstet Gynecol Reprod Biol. 2016 Dec;207:141-146. doi: 10.1016/j.ejogrb.2016.10.026. Epub 2016 Nov 8.

PMID:
27863271
9.

Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial.

Zethraeus N, Dreber A, Ranehill E, Blomberg L, Labrie F, von Schoultz B, Johannesson M, Hirschberg AL.

J Clin Endocrinol Metab. 2016 Nov;101(11):4046-4053. Epub 2016 Aug 15.

PMID:
27525531
10.

Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.

Coelingh Bennink HJT, Zimmerman Y, Laan E, Termeer HMM, Appels N, Albert A, Fauser BCJM, Thijssen JHH, van Lunsen RHW.

Contraception. 2017 Nov;96(5):322-329. doi: 10.1016/j.contraception.2016.06.022. Epub 2016 Jul 5.

11.

Efficacy of combined hormonal vaginal ring in comparison to combined hormonal pills in heavy menstrual bleeding.

Dahiya P, Dalal M, Yadav A, Dahiya K, Jain S, Silan V.

Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:147-51. doi: 10.1016/j.ejogrb.2016.05.009. Epub 2016 May 20.

PMID:
27285306
12.

Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.

Dinger J, Möhner S, Heinemann K.

Contraception. 2016 May;93(5):378-85. doi: 10.1016/j.contraception.2016.01.012. Epub 2016 Jan 26.

PMID:
26825258
13.

From single chemicals to mixtures--reproductive effects of levonorgestrel and ethinylestradiol on the fathead minnow.

Runnalls TJ, Beresford N, Kugathas S, Margiotta-Casaluci L, Scholze M, Scott AP, Sumpter JP.

Aquat Toxicol. 2015 Dec;169:152-67. doi: 10.1016/j.aquatox.2015.10.009. Epub 2015 Oct 17.

14.

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.

Duijkers IJ, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, Mawet M, Foidart JM, Coelingh Bennink HJ.

Eur J Contracept Reprod Health Care. 2015;20(6):476-89. doi: 10.3109/13625187.2015.1074675.

15.

Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.

Lobo Abascal P, Luzar-Stiffler V, Giljanovic S, Howard B, Weiss H, Trussell J.

Eur J Contracept Reprod Health Care. 2016;21(1):88-91. doi: 10.3109/13625187.2015.1059416. Epub 2015 Jun 26.

16.
17.

Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.

Sivasubramanian R, Chakraborty A, Rouzade-Dominguez ML, Neelakantham S, Jakab A, Mensinga T, Legangneux E, Woessner R, Ufer M.

Int J Clin Pharmacol Ther. 2015 Jul;53(7):550-6. doi: 10.5414/CP202321.

PMID:
25943176
18.

Transdermal contraception methods: today's patches and new options on the horizon.

Nelson AL.

Expert Opin Pharmacother. 2015 Apr;16(6):863-73. doi: 10.1517/14656566.2015.1022531. Review.

PMID:
25800084
19.

Mixture effects of levonorgestrel and ethinylestradiol: estrogenic biomarkers and hormone receptor mRNA expression during sexual programming.

Säfholm M, Jansson E, Fick J, Berg C.

Aquat Toxicol. 2015 Apr;161:146-53. doi: 10.1016/j.aquatox.2015.02.004. Epub 2015 Feb 11.

PMID:
25703176
20.

Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study.

Stocco B, Fumagalli HF, Franceschini SA, Martinez EZ, Marzocchi-Machado CM, de Sá MF, Toloi MR.

Medicine (Baltimore). 2015 Jan;94(4):e385. doi: 10.1097/MD.0000000000000385.

Supplemental Content

Loading ...
Support Center